


1fw

<b>INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(e)</b>  Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	UCAL-280
	First Named Inventor	MUCKE, LENNART
	Application Number	10/809,777
	Confirmation No.	8698
	Filing Date	March 24, 2004
	Group Art Unit	1632
	Examiner Name	MONTANARI, DAVID A.
Title: "METHODS OF DETECTING NEUROLOGICAL DISORDERS"		

Sir:

Applicants submit herewith patents and/or publications which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. While this Statement may be "material" pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any patent, publication, or other information referred to therein is "prior art" for this invention unless specifically designated as such. A listing of patents and/or publications is shown on enclosed Form PTO-SB/08A and a copy of each patent and/or publication is also enclosed.


Each item of information contained in the Information Disclosure Statement filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement (37 C.F.R. 1.97(e)(1)). A copy of the communication is enclosed for the Examiner's convenience.

The Examiner is requested to make the citations listed on the enclosed PTO-SB/08A of record in this application. Applicants would appreciate the Examiner initialing and returning the initialed copy of form PTO-SB/08A, indicating the references have been considered and made of record herein.

No fee is believed due as this statement is being submitted within three months of the mailing date of the enclosed foreign communication. However, if it is determined that fees are required, the Commissioner is hereby authorized to charge any necessary fees associated with this communication or credit any overpayment to Deposit Account No. 50-0815, Order No. UCAL-280.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: Sept. 7, 2005

By:   
Paula A. Borden, Reg. No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/809,777
		Filing Date	March 24, 2004
		First Named Inventor	MUCKE, LENNART
		Art Unit	1632
Examiner Name	MONTANARI, DAVID A.		
Sheet 1 of 1	Attorney Docket Number	UCAL-280	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Allen, et al. "Elevation of Neuropeptide Y (NPY) in Substantia Innominata in Alzheimer's Type Dementia. J. Neurolog. Sciences, 1984, 64, pp. 325-331	
		Chan-Palay et al. II "Cortical neurons immunoreactive with antisera against Neuropeptide Y are altered in Alzheimer's-Type Dementia" J. comparative Neurology, 1985, 238, pp. 390-300	
		Minthon et al. "Cerebrospinal fluid Neuropeptide Y-like Immunoreactive levels in Dementia of Alzheimer Type and Dementia with Frontotemporal Degeneration of Non-Alzheimer Type. Dementia, 1990, 1 pp-262-266	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.